Ricardo Air Quality and Economic Expertise to Help European Commission Reduce Hundreds of Thousands of Premature Deaths From Air Pollution
15.11.2022 03:01:00 EET | Business Wire | Press release
Ricardo, a global strategic environmental and engineering consulting company, has significantly contributed to the European Commission’s revision of the Ambient Air Quality Directive which sets air quality standards for European Union Member States. This Directive underpins the improvement of air quality to reduce the 300,000 premature deaths a year and a significant number of noncommunicable diseases such as asthma, cardiovascular problems and lung cancer, which are still attributed to air pollution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221114005544/en/
Smog in the city of Milan, Italy (Photo: Business Wire)
Led by Ricardo, a team of air quality experts, including IIASA, Met.No, VITO and Trinomics, carried out an impact assessment into options to revise the legislation. Using scenario modelling to 2050, Ricardo considered what the potential impacts of the new air quality standards could be in relation to public health, the environment and business. Ricardo provided economic expertise to the impact assessment which shows that the benefits of the proposed revision for society far outweigh the costs. The main benefits expected are related to health: including reduced mortality and morbidity, reduced healthcare expenditure, reduced absence from work due to illness and increased productivity at work. Additionally, key benefits for the environment include reduced ozone-related crop yield losses.
A further study, also led by Ricardo, set out suggestions to improve support for local authorities in achieving cleaner air through strengthening air quality monitoring, modelling and plans.
Dr Beth Conlan, Technical Director – Air Quality at Ricardo said: “Ricardo has the longest-established specialist air quality team in the world and, with over 130 experts, one of the largest, and this is reflected in the UK’s position as a world-leader in air quality expertise. As our corporate mission is to create a safe and sustainable world, we are honoured that the European Commission chose to entrust this seminal project to us, which will significantly reduce deaths, improve people’s quality of life and public health in general. Legislation really does push forward change and, in my thirty years of working in this sector, this regulatory revision is likely to be the most far reaching and valuable in terms of improving air quality.”
Ricardo has provided expertise to the European Union (EU) in air quality and climate change since the 1990s, supporting the EU’s drive to lower emissions, through the Green Deal, and air quality directives – the last one of which was enacted in 2008. Ricardo’s air quality team has very well-established capability in air quality assessment and management practice. It was this capability, together with Ricardo’s economic expertise and proven track record in successfully delivering co-beneficial air quality and climate change programmes for the European Commission that led to the Ricardo-managed air quality team working on this project.
In the UK, Ricardo’s air quality expertise is helping the national Government shape strategies that offer routes to delivering national emissions reduction commitments such as the UK’s Clean Air Strategy, the National Air Pollution Control Plan, National Emission Ceilings targets, Environment Act Air Quality targets, and the UK’s net zero strategy, as well as international objectives through the Gothenburg Protocol.
Ends
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005544/en/
Contact information
Media contacts:
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
